Skip to main content
CVE-2025-64642VulnerabilityPublished

Mirion Medical EC2 Software NMIS BioDose

Affects CISA Mirion MedicalSource GCVE Database

0
Compare
Authoritative record:CVE-2025-64642· High 7.1

Not known to be exploited · CVSS 7.1 High : upgrade to 23.0 soon.

Data as of 21 Nov 2026, 03:53 UTC

CVSS 4.0 base score
7.1High
How severe the flaw is on the 0–10 CVSS scale.
Patch
Available – fixed in 23.0
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:N/VC:L/VI:H/VA:H/SC:N/SI:N/SA:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 2 Dec 2025

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponized: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 20 Nov 2026.

What to do

Upgrade CISA Mirion Medical to 23.0.

Affected software

ProductAffectedFixed in
CISA Mirion MedicalAffected
  • <23.0
Fixed in
  • 23.0

AI-suggested

A fixed version 23.0 of Mirion Medical EC2 Software NMIS BioDose is available and should be applied to remediate these vulnerabilities. Users should upgrade to version 23.0. CISA recommends implementing defensive measures to minimize exploitation risk.

Description

Multiple vulnerabilities have been identified in Mirion Medical EC2 Software NMIS BioDose versions prior to 23.0. These include issues related to improper access control, authentication bypass, and hardcoded credentials. A fixed version 23.0 is available to address these vulnerabilities. CISA recommends users implement defensive measures to reduce exploitation risk.

References

Community reviews

Loading reviews…